NASDAQ: SLDB

Solid Biosciences Inc Stock Forecast, Predictions & Price Target

The consensus among 6 Wall Street analysts covering (NASDAQ: SLDB) stock is to Strong Buy SLDB stock.

Out of 6 analysts, 3 (50%) are recommending SLDB as a Strong Buy, 3 (50%) are recommending SLDB as a Buy, 0 (0%) are recommending SLDB as a Hold, 0 (0%) are recommending SLDB as a Sell, and 0 (0%) are recommending SLDB as a Strong Sell.

If you're new to stock investing, here's how to buy Solid Biosciences stock.

(NASDAQ: SLDB) Solid Biosciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.5%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.08%.

Solid Biosciences's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast SLDB's revenue for 2024 to be $664,521,035, with the lowest SLDB revenue forecast at $664,521,035, and the highest SLDB revenue forecast at $664,521,035. On average, 1 Wall Street analysts forecast SLDB's revenue for 2025 to be $668,296,723, with the lowest SLDB revenue forecast at $668,296,723, and the highest SLDB revenue forecast at $668,296,723.

In 2028, SLDB is forecast to generate $2,359,049,675 in revenue, with the lowest revenue forecast at $973,749,858 and the highest revenue forecast at $3,427,569,294.

According to 6 Wall Street analysts that have issued a 1 year SLDB price target, the average SLDB price target is $20.33, with the highest SLDB stock price forecast at $40.00 and the lowest SLDB stock price forecast at $9.00.

On average, Wall Street analysts predict that Solid Biosciences's share price could reach $20.33 by Mar 28, 2025. The average Solid Biosciences stock price prediction forecasts a potential upside of 131.85% from the current SLDB share price of $8.77.

(NASDAQ: SLDB) forecast ROE is N/A, which is considered weak.